Welcome!
IHH Healthcare (IHH)
Sustainability
IHH Healthcare announces sustainability commitments in launch of first standalone sustainability report
IHH’s sustainability goals were set out across four stakeholder pillars, which are "patients", "people", "public" and "planet".
May 02, 2023
Healthcare
Large-cap healthcare stocks: Hefty, hearty and healthy
Covid-19 may be over, but these hospital players are still seeing growth from the economic recovery.
March 09, 2023
Results
IHH Healthcare reports FY2022 earnings of RM1.55 bil, 16.9% lower y-o-y
A first and final dividend of 2.16 cents has been declared for the year.
February 28, 2023
Healthcare
PLife REIT and IHH Healthcare conduct major refurbishment works at Mount Elizabeth Hospital
The project, which will cost $350 million, will be jointly funded by both PLife REIT and IHH Healthcare.
January 03, 2023
Broker's Calls
Private hospitals may benefit from rise in Covid-19 cases: DBS
DBS has kept “buy” on Raffles Medical Group and IHH Healthcare with target prices of $1.63 and RM7.90 ($2.37) respectively.
October 25, 2022
Healthcare
IHH Healthcare says no wrongdoing found in Fortis investment
In its statement, IHH expressed its commitment to “stand firm” on Fortis’ side to “continue this growth journey”.
September 26, 2022
Broker's Calls
Broker's Digest: Parkway Life REIT, IHH Healthcare, Keppel Corporation, Yangzijiang Shipbuilding, Kimly
See what the analysts have to say this week.
September 15, 2022
Broker's Calls
IHH has 'plenty [of] opportunities to grow' despite termination of Ramsay Sime-Darby acquisition: CGS-CIMB
CGS-CIMB is keeping its 'add' call and target price of RM8.07 ($2.50) on IHH.
September 13, 2022
M&A
Discussions between IHH to acquire Ramsay Sime Darby Health Care Sdn Bhd have been terminated
IHH Healthcare, on March 22, announced that it has proposed to acquire 100% of Ramsay Sime Darby Health Care Sdn Bhd
September 09, 2022
Broker's Calls
Analysts optimistic on IHH Healthcare on further recovery in core businesses
IHH is currently trading at a very attractive FY22 EV/ebitda of 14x, close to -2 SD of its historical range.
August 30, 2022